|
PSCI-21-039 |
A Phase II, Multicenter, Randomized, Open-Label Trial of GEN1046 as monotherapy and in Combination with Anti-cancer Therapy in Subjects with Relapsed/Refractory Metastatic Non-Small Cell Lung Cancer who failed first-line Standard of Care therapy with an Immune Checkpoint Inhibitor |
|
PSCI-21-042 |
Prospective evaluation of potential effects of repeated gadoliniumbased contrast agent (GBCA) administrations of the same GBCA on motor and cognitive functions in neurologically normal adults in comparison to a non-GBCA exposed control group ODYSSEY |
|
PSCI-21-045 |
Trial Assessing Light-Intensity Exercise on the Health of Older Breast Cancer Survivors (TALIE-HO Breast Cancer Survivors) |
|
PSCI-21-050 |
SurvivorLink: Scalability of an Electronic Personal Health Record for Cancer Survivors and Caregivers at Pediatric Cancer Centers ( SurvivorLink Scalability ) |
|
PSCI-21-051 |
HPV ECHO: Increasing the adoption of evidence-based communication strategies for HPV vaccination in rural primary care practices. |
|
PSCI-21-062 |
A Phase 3 Randomized Trial for Patients with de novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 with GO, and the Addition of the FLT3Inhibitor Gilteritinib for Patients with FLT3 Mutations |
|
PSCI-21-098 |
NRG-BR007: A Phase III Clinical Trial Evaluating Deescalation of Breast Radiation for Conservative Treatment of Stage I, Hormone sensitive, HER2- Negative Oncotype recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA) |
|
PSCI-21-111 |
EA2197: Optimal Perioperative Therapy For Incidental Gallbladder Cancer (OPT-IN): A Randomized Phase II/III Trial |
|
PSCI-21-115 |
EAA173 Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM) |
|
PSCI-21-117 |
Multicenter Phase 3 Pivotal Study to Evaluate the Safety and Efficacy of TOOKAD (padeliporfin) Vascular Targeted Photodynamic Therapy in the Treatment of Low Grade Upper Tract Urothelial Cancer |
